Brimotale Plus Eye Drop contains Brimonidine 0.2% w/v, a selective alpha-2 adrenergic agonist used to lower elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Its proven formulation ensures effective and well-tolerated long-term therapy.
The eye drop works by reducing aqueous humor production and increasing uveoscleral outflow, helping to maintain controlled eye pressure and protect the optic nerve, thereby supporting long-term visual health.
From a franchise perspective, Brimotale Plus Eye Drop is a high-demand anti-glaucoma ophthalmic product, widely prescribed in eye hospitals, ophthalmology clinics, and specialty glaucoma centers, ensuring consistent prescriptions and repeat sales.
Adding Brimotale Plus Eye Drop to your portfolio strengthens the ophthalmic anti-glaucoma segment, offering long-term growth, strong prescriber confidence, and enhanced portfolio credibility for PCD pharma franchise partners.